Previous 10 | Next 10 |
Chinese biotech I-Mab ( NASDAQ: IMAB ) on Tuesday said its U.S. partner AbbVie ( ABBV ) would discontinue a phase 1b study evaluating a combination treatment including its anti-CD47 antibody therapy lemzoparlimab for two types of cancers. ABBV stock and U.S.-listed share...
Gainers: Liberty TripAdvisor ( LTRPB ) +209% . Virax Biolabs Group ( VRAX ) +130% . Qurate Retail ( QRTEB ) +80% . MediaCo ( MDIA ) +67% . Nanobiotix ( NTX ) +47% . Aethlon Medical ( AEMD ) +46% . GeoVax ( ...
Gainers: Virax Biolabs ( VRAX ) +62% . Aethlon Medical ( AEMD ) +46% . GeoVax Labs ( GOVX ) +46% . Celyad Oncology ( CYAD ) +40% . Outset Medical ( OM ) +28% . Losers: Otonomy ( OTIC ) -77% . Kazia Therapeu...
I-Mab ( NASDAQ: IMAB ) said the first patient in China had been treated with its TJ-CD4B in a Phase 1 international multi-center clinical trial for patients with solid tumors, including gastric cancer, gastroesophageal junction carcinoma. TJ-CD4B binds to Claudin ...
I-Mab Announces First Patient Dosed in Phase 1 Clinical Trial of Claudin 18.2 and 4-1BB Bispecific Antibody TJ-CD4B in Solid Tumors in China PR Newswire GAITHERSBURG, Md. and SHANGHAI , July 22, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq:...
I-Mab to Present Phase 2 Clinical Data of CD47 Antibody Lemzoparlimab at ESMO Congress 2022 PR Newswire GAITHERSBURG, Md. and SHANGHAI , July 18, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company com...
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due t...
I-Mab to Host 2022 R&D Day I-Mab to Host 2022 R&D Day PR Newswire GAITHERSBURG, MD . and SHANGHAI , July 6, 2022 /PRNewswire/ -- I-Mab ("I-Mab" or the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the d...
The biotech indices have fallen considerably. Many biotechs are trading with negative enterprise values despite unprecedented innovation in the biotech industry. I-Mab is headed for commercialization with enough cash to carry then into 2025 with multiple products hitting the ...
I-Mab Receives Top Rankings in Five Categories by Institutional Investor PR Newswire GAITHERSBURG, Md. and SHANGHAI , June 23, 2022 /PRNewswire/ -- I-Mab ("I-Mab" or the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed t...
News, Short Squeeze, Breakout and More Instantly...
I-Mab Announces Leadership Transitions PR Newswire ROCKVILLE, Md. , July 15, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company" or "I-Mab"), a U.S.-based, global biotech company, announced today that the Board of Directors of the Company has appointed Mr. ...
I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer PR Newswire ROCKVILLE, Md. , June 6 , 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company"), a U.S.-based, global biotech company, exclusively focused on the development and potential commercial...
I-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers PR Newswire I-Mab enters clinical collaboration with Bristol Myers Squibb to evaluate Claudin 18.2 x 4-1BB bispecific anti...